Compass Pathways PLC
CMPS5.450USD
-0.140-2.50%
收盤 11/07, 16:00（美東）報價延遲15分鐘
523.21M總市值
虧損本益比TTM
關於 Compass Pathways PLC 公司
Compass Pathways plc 是一家總部位於英國的生物技術公司，致力於加速患者獲得心理健康領域循證創新的途徑。該公司致力於裸蓋菇素治療的開發，其中其研究性 COMP360 裸蓋菇素與心理支持 COMP360 裸蓋菇素治療相結合使用。COMP360 是其專有的裸蓋菇素配方，包括其藥物級多晶型裸蓋菇素，經過優化以提高穩定性和純度。該公司的初始重點是難治性抑鬱症 (TRD)，包括當前治療模式無法充分滿足的患者。該公司已啓動其 III 期計劃，評估其 COMP360 裸蓋菇素在 TRD 中的治療效果。此外，該公司正在開展 PTSD 和神經性厭食症的 II 期試驗。它還爲在嚴重未滿足需求的領域開展由研究人員發起的 COMP360 裸蓋菇素研究的研究機構提供支持。
Compass Pathways PLC簡介
公司代碼CMPS
公司名稱Compass Pathways PLC
上市日期Sep 18, 2020
CEOMr. Kabir Nath
員工數量166
證券類型Depository Receipt
年結日Sep 18
公司地址3Rd Floor, 1 Ashley Road
城市ALTRINCHAM
上市交易所NASDAQ Global Select Consolidated
國家United Kingdom
郵編WA14 2DT
電話17166766461
網址https://compasspathways.com/
公司代碼CMPS
上市日期Sep 18, 2020
CEOMr. Kabir Nath
Compass Pathways PLC公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Robert McQuade, Ph.D.
Dr. Robert McQuade, Ph.D.
Independent Director
Independent Director
1.59M
--
Mr. Thomas Lonngren
Mr. Thomas Lonngren
Independent Director
Independent Director
89.05K
--
Mr. Kabir Nath
Mr. Kabir Nath
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
29.07K
+944.11%
Mr. David Norton
Mr. David Norton
Independent Director
Independent Director
20.36K
+17.06%
Dr. Annalisa M. Jenkins
Dr. Annalisa M. Jenkins
Independent Director
Independent Director
19.48K
+17.97%
Ms. Teri Loxam
Ms. Teri Loxam
Chief Financial Officer
Chief Financial Officer
11.21K
-86.53%
Dr. Guy Goodwin
Dr. Guy Goodwin
Chief Medical Officer
Chief Medical Officer
1.99K
--
Mr. Justin Gover
Mr. Justin Gover
Director
Director
--
--
Ms. Daphne Karydas
Ms. Daphne Karydas
Independent Director
Independent Director
--
--
Dr. Wayne Joseph Riley, M.D.
Dr. Wayne Joseph Riley, M.D.
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Robert McQuade, Ph.D.
Dr. Robert McQuade, Ph.D.
Independent Director
Independent Director
1.59M
--
Mr. Thomas Lonngren
Mr. Thomas Lonngren
Independent Director
Independent Director
89.05K
--
Mr. Kabir Nath
Mr. Kabir Nath
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
29.07K
+944.11%
Mr. David Norton
Mr. David Norton
Independent Director
Independent Director
20.36K
+17.06%
Dr. Annalisa M. Jenkins
Dr. Annalisa M. Jenkins
Independent Director
Independent Director
19.48K
+17.97%
Ms. Teri Loxam
Ms. Teri Loxam
Chief Financial Officer
Chief Financial Officer
11.21K
-86.53%
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 8月19日 週二
更新時間: 8月19日 週二
持股股東
股東類型
持股股東
持股股東
佔比
Deep Track Capital LP
9.20%
RTW Investments L.P.
8.56%
Atai Life Sciences AG
6.03%
Nantahala Capital Management, LLC
4.35%
Vivo Capital, LLC
3.50%
其他
68.36%
持股股東
持股股東
佔比
Deep Track Capital LP
9.20%
RTW Investments L.P.
8.56%
Atai Life Sciences AG
6.03%
Nantahala Capital Management, LLC
4.35%
Vivo Capital, LLC
3.50%
其他
68.36%
股東類型
持股股東
佔比
Hedge Fund
27.36%
Investment Advisor/Hedge Fund
13.92%
Investment Advisor
7.51%
Individual Investor
6.10%
Corporation
6.03%
Venture Capital
3.92%
Research Firm
1.64%
Bank and Trust
1.41%
Endowment Fund
0.22%
其他
31.89%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
281
53.81M
56.04%
-10.94M
2025Q2
278
64.72M
67.46%
+3.21M
2025Q1
287
65.16M
70.41%
+4.19M
2024Q4
278
44.23M
47.77%
-10.96M
2024Q3
271
50.07M
70.05%
-2.63M
2024Q2
274
48.30M
70.14%
-3.09M
2024Q1
276
47.45M
68.96%
+541.76K
2023Q4
283
43.21M
76.55%
-1.53M
2023Q3
283
43.38M
82.47%
+3.50M
2023Q2
280
29.35M
64.55%
-6.45M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Deep Track Capital LP
8.83M
9.2%
-28.64K
-0.32%
Jun 30, 2025
RTW Investments L.P.
8.22M
8.57%
+2.68M
+48.46%
Jun 30, 2025
Atai Life Sciences AG
6.91M
7.2%
--
--
Mar 05, 2025
Nantahala Capital Management, LLC
4.18M
4.36%
+1.35M
+47.74%
Jun 30, 2025
Vivo Capital, LLC
3.36M
3.5%
--
--
Jun 30, 2025
Goldsmith (George Jay)
2.05M
2.14%
-129.33K
-5.93%
Mar 31, 2025
Malievskaia (Ekaterina)
2.03M
2.11%
-149.38K
-6.86%
Mar 31, 2025
GMT Capital Corp.
1.78M
1.86%
--
--
Jun 30, 2025
PFM Health Sciences, LP
1.78M
1.85%
+1.33M
+294.28%
Jun 30, 2025
Woodline Partners LP
1.76M
1.83%
+1.08K
+0.06%
Jun 30, 2025
查看更多
持股ETF
更新時間: 11月6日 週四
更新時間: 11月6日 週四
機構名稱
佔比
AdvisorShares Psychedelics ETF
9.69%
Simplify Propel Opportunities ETF
2.51%
ARK Genomic Revolution ETF
1.06%
Virtus LifeSci Biotech Clinical Trials ETF
0.91%
ALPS Medical Breakthroughs ETF
0.32%
Invesco Nasdaq Biotechnology ETF
0.06%
SPDR S&P International Small Cap ETF
0.06%
ProShares Ultra Nasdaq Biotechnology
0.05%
iShares Biotechnology ETF
0.03%
Putnam Sustainable Future ETF
0%
查看更多
AdvisorShares Psychedelics ETF
佔比9.69%
Simplify Propel Opportunities ETF
佔比2.51%
ARK Genomic Revolution ETF
佔比1.06%
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.91%
ALPS Medical Breakthroughs ETF
佔比0.32%
Invesco Nasdaq Biotechnology ETF
佔比0.06%
SPDR S&P International Small Cap ETF
佔比0.06%
ProShares Ultra Nasdaq Biotechnology
佔比0.05%
iShares Biotechnology ETF
佔比0.03%
Putnam Sustainable Future ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
